Bluebird Bio reported $-122152000 in Pre-Tax Profit for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Pre Tax Profit Change
Agios Pharmaceuticals AGIO:US $ -94.77M 3.81M
Alnylam Pharmaceuticals ALNY:US $ -239.36M 20.95M
Amgen AMGN:US $ 2727M 56M
Applied Genetic Technologies AGTC:US $ -14.24M 4.87M
Arrowhead Research ARWR:US $ 44.37M 107.24M
Biogen BIIB:US $ 903.4M 316.6M
Biomarin Pharmaceutical BMRN:US $ 26.19M 92.76M
Bluebird Bio BLUE:US $ -122.15M 10.09M
Immunogen IMGN:US $ -24.14M 13.03M
Intercept Pharmaceuticals ICPT:US $ -17.28M 19M
IONIS PHARMACEUT IONS:US $ -64M 289M
Mirati Therapeutics MRTX:US $ -188.39M 11.23M
Moderna Inc MRNA:US 4.23B 1.18B
Nektar Therapeutics NKTR:US $ -90.27M 55.38M
Novartis NOVN:VX SF 3912M 230M
Pfizer PFE:US $ 11328M 4083M
Ptc Therapeutics PTCT:US $ -121.89M 16.72M
Regeneron Pharmaceuticals REGN:US $ 1119.1M 1986M
Sangamo Biosciences SGMO:US $ -43.92M 6.36M
Sarepta Therapeutics SRPT:US $ -104.15M 17.74M
Seattle Genetics SGEN:US $ -135.24M 41.73M
Ultragenyx Pharmaceutical RARE:US $ -151.76M 29.32M
YTE INCY:US $ 172.84M 1.75M